Theriva Biologics Inc.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase … Read more
Theriva Biologics Inc. (TOVX) - Total Assets
Latest total assets as of September 2025: $30.84 Million USD
Based on the latest financial reports, Theriva Biologics Inc. (TOVX) holds total assets worth $30.84 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Theriva Biologics Inc. - Total Assets Trend (1993–2024)
This chart illustrates how Theriva Biologics Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Theriva Biologics Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Theriva Biologics Inc.'s total assets of $30.84 Million consist of 46.1% current assets and 54.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 32.8% |
| Accounts Receivable | $3.32 Million | 9.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $17.36 Million | 49.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1993–2024)
This chart illustrates how Theriva Biologics Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Theriva Biologics Inc.'s current assets represent 46.1% of total assets in 2024, a decrease from 94.4% in 1993.
- Cash Position: Cash and equivalents constituted 32.8% of total assets in 2024, down from 94.4% in 1993.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 49.0% of total assets, an increase from 0.0% in 1993.
- Asset Diversification: The largest asset category is intangible assets at 49.1% of total assets.
Theriva Biologics Inc. Competitors by Total Assets
Key competitors of Theriva Biologics Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Theriva Biologics Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Theriva Biologics Inc. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Theriva Biologics Inc. is currently not profitable relative to its asset base.
Theriva Biologics Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.90 | 2.67 | 2.67 |
| Quick Ratio | 0.90 | 2.67 | 2.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.10 Million | $ 12.21 Million | $ 4.97 Million |
Theriva Biologics Inc. - Advanced Valuation Insights
This section examines the relationship between Theriva Biologics Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.18 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | -36.0% |
| Total Assets | $35.35 Million |
| Market Capitalization | $6.13 Million USD |
Valuation Analysis
Below Book Valuation: The market values Theriva Biologics Inc.'s assets below their book value (0.17 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Theriva Biologics Inc.'s assets decreased by 36.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Theriva Biologics Inc. (1993–2024)
The table below shows the annual total assets of Theriva Biologics Inc. from 1993 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $35.35 Million | -35.98% |
| 2023-12-31 | $55.22 Million | -23.16% |
| 2022-12-31 | $71.86 Million | +2.13% |
| 2021-12-31 | $70.36 Million | +736.68% |
| 2020-12-31 | $8.41 Million | -51.20% |
| 2019-12-31 | $17.23 Million | -42.82% |
| 2018-12-31 | $30.14 Million | +60.00% |
| 2017-12-31 | $18.84 Million | -16.27% |
| 2016-12-31 | $22.50 Million | -27.06% |
| 2015-12-31 | $30.84 Million | +61.12% |
| 2014-12-31 | $19.14 Million | +17.76% |
| 2013-12-31 | $16.26 Million | +21.11% |
| 2012-12-31 | $13.42 Million | +79.55% |
| 2011-12-31 | $7.48 Million | +81.85% |
| 2010-12-31 | $4.11 Million | +0.87% |
| 2009-12-31 | $4.08 Million | -44.81% |
| 2008-12-31 | $7.39 Million | -45.83% |
| 2007-12-31 | $13.63 Million | +8.93% |
| 2006-12-31 | $12.52 Million | +769.17% |
| 2005-12-31 | $1.44 Million | -4.93% |
| 2002-12-31 | $1.51 Million | -26.34% |
| 2001-12-31 | $2.06 Million | -62.27% |
| 2000-12-31 | $5.45 Million | +7.96% |
| 1999-12-31 | $5.05 Million | +74.09% |
| 1998-12-31 | $2.90 Million | +314.29% |
| 1997-12-31 | $700.00K | -75.00% |
| 1996-12-31 | $2.80 Million | +27.27% |
| 1995-12-31 | $2.20 Million | +450.00% |
| 1994-12-31 | $400.00K | -77.78% |
| 1993-12-31 | $1.80 Million | -- |